FDA Affirms VIBRAMYCIN Oral Suspension Was Not Pulled Over Safety or Effectiveness
April 09, 2025
April 09, 2025
WASHINGTON, April 9 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has determined that VIBRAMYCIN (doxycycline) for oral suspension, equivalent to 25 mg base per 5 mL, was not removed from the market due to any safety or efficacy issues.
The ruling, published in the Federal Register on April 9, 2025, ensures that the agency will continue approving abbreviated new drug applications referencing the discontinued product, provided those applicat . . .
The ruling, published in the Federal Register on April 9, 2025, ensures that the agency will continue approving abbreviated new drug applications referencing the discontinued product, provided those applicat . . .